This study is in progress, not accepting new patients
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCSD UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Ashutosh Lal (ucsf)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Ashutosh Lal (ucsf)
I am a hematologist at UCSF Benioff Children’s Hospital Oakland, Director of Clinical Hematology, and Director of the Comprehensive Thalassemia Center and Iron Disorders Program. I spend 50% time in clinic and 50% in research. My long-term academic and are thalassemia, iron overload, and nutrition.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Agios Pharmaceuticals, Inc.
- ID
- NCT04770779
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 258 people participating
- Last Updated